MARKET

NVAX

NVAX

Novavax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.61
+1.75
+12.63%
After Hours: 15.54 -0.07 -0.45% 19:59 04/03 EDT
OPEN
13.74
PREV CLOSE
13.86
HIGH
15.69
LOW
13.60
VOLUME
9.12M
TURNOVER
--
52 WEEK HIGH
17.71
52 WEEK LOW
3.540
MARKET CAP
804.37M
P/E (TTM)
-2.7506
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NVAX stock price target is 19.50 with a high estimate of 24.00 and a low estimate of 7.00.

EPS

NVAX News

More
  • These D.C.-area biotech companies are making progress on COVID-19. Heres the latest.
  • American City Business Journals · 4h ago
  • Novavax (NVAX): Strong Industry, Solid Earnings Estimate Revisions
  • Zacks · 9h ago
  • Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
  • Zacks · 1d ago
  • Exclusive: Rockville bio raising $50M, building COVID-19 vaccine and plotting IPO
  • American City Business Journals · 1d ago

Industry

Biotechnology & Medical Research
-0.74%
Pharmaceuticals & Medical Research
-0.56%

Hot Stocks

Symbol
Price
%Change

About NVAX

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
More

Webull offers kinds of Novavax, Inc. stock information, including NASDAQ:NVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVAX stock news, and many more online research tools to help you make informed decisions.